Kiora Pharmaceuticals has entered into an exclusive license agreement with Chong Kun Dang Pharmaceutical Corporation for intellectual property related to inherited retinal disease, with an effective date of August 20, 2026. This strategic licensing deal is significant for the company's pipeline and potential future commercial activities.